Recent patents reveal microtubules as persistent promising target for novel drug development for cancers

Recent Patents on Anti-Infective Drug Discovery

Volumn 4, Issue 3, 2009, Pages 164-182

  Bughani, Usha ^a   Li, Shiwang ^a   Joshi, Harish C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti tubulin drugs; Cancer; Noscapine; Patents; Taxanes; Vincas

Indexed keywords

3 HALOACETAMIDO BENZOYL ETHYL ESTER; 6 SHOGAOL; 9,10 DIDEHYDROEPOTHILONE D; \D 24851; \SC 2 71; ALKALOID DERIVATIVE; ANTINEOPLASTIC AGENT; BENZOYLPHENYLUREA DERIVATIVE; BETA TUBULIN; COLCHICINE; COMBRESTATIN A4 PHOSPHATE; CREMOPHOR; CYTOTOXIC AGENT; D 24851; DOCETAXEL; DOXORUBICIN; E 7820; EPOTHILONE B; EPOTHILONE DERIVATIVE; FLUOROURACIL; IXABEPILONE; N (3 CYANO 4 METHYL 1H INDOLE 7 YL) 3 CYANOBENZENE SULFONAMIDE; NAVELBINE; NOSCAPINE; PACLITAXEL; SC 2 71; TAXANE DERIVATIVE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VINCRISTINE; VINDESINE; VINFLUNINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER THERAPY; CARDIOTOXICITY; CELL CYCLE ARREST; CLINICAL TRIAL; CYTOTOXICITY TEST; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GERM CELL TUMOR; GLIOBLASTOMA; GROWTH INHIBITION; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; IC 50; IMMUNE DEFICIENCY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MICROTUBULE; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PATENT; PERIPHERAL NEUROPATHY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SENSORY NEUROPATHY; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH CANCER; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; MICROTUBULES; NEOPLASMS; NOSCAPINE; PATENTS AS TOPIC; TUBULIN;

EID: 70350776966     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489109789318532     Document Type: Article

References (187)

1. zur Hausen H. Viral oncogenesis. Microbes and malignancy. Infection as a cause of human cancer. J Parsonnet New York: Oxford Univ Press 1999; 107-130.
2. zur Hausen H. Novel human polyomaviruses-re-emergence of a well known virus family as possible human carcinogens. Int J Cancer 2008; 123: 247-250.
3. zur Hausen H. Papillomaviruses in the causation of human cancers -a brief historical account. Virology 2009; 384: 260-265.
4. Zorn KC, Gofrit ON, Steinberg GD, et al. Evolution of robotic surgery in the treatment of localized prostate cancer. Curr Treat Options Oncol 2007; 8: 197-210.
5. Medeiros LR, Rosa DD, Bozzetti MC, et al. Laparoscopy versus laparotomy for benign ovarian tumour. Cochrane Database Syst Rev 2009; 2: CD004751.
6. Luh SP, Liu HP. Video-assisted thoracic surgery - the past, present status and the future. J Zhejiang Univ Sci B 2006; 7: 118-128.
7. Gerber DE, Chan TA. Recent advances in radiation therapy. Am Fam Physician 2008; 78: 1254-1262.
8. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17: 1061-1070.
9. Waldmann TA. Immunotherapy: Past, present and future. Nat Med 2003; 9: 269-277.
10. Schwaber J, Cohen EP. Human X mouse somatic cell hybrid clone secreting immunoglobulins of both parental types. Nature 1973; 244: 444-447.
11. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-129.
12. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-274.
13. Ménard S, Pupa SM, Campiglio M, et al. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-6578.
14. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and futuredirections. Clin Cancer Res 2003; 9: 5078-5084.
15. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907-913.
16. Quesada JR, Hersh EM, Manning J, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986; 68: 493-497.
17. Giarelli E. Cancer vaccines: A new frontier in prevention and treatment. Oncology (Williston Park) 2007; 21: 11-17.
18. Pejawar-Gaddy S, Finn OJ. Cancer vaccines: Accomplishments and challenges. Crit Rev Oncol Hematol 2008; 67: 93-102.
19. Lollini PL, Cavallo F, Nanni P, et al. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6: 204-216.
20. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859.
21. Mast EE, Margolis HS, Fiore AE, et al. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of infants, children, and adolescents. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR Morb Mortal Rep Wkly 2005; 54: 1-23.
22. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116: 1167-1173.
23. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997; 13: 83-117.
24. Howard J, Hyman AA. Dynamics and mechanics of the microtubule plus end. Nature 2003; 422: 753-758.
25. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.
26. Pasquier E, Kavallaris M. Microtubules: A dynamic target in cancer therapy. IUBMB Life 2008; 60: 165-170.
27. Bhattacharyya B, Panda D, Gupta S, et al. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008; 28: 155-183.
28. Wittmann T, Hyman A, Desai A. The spindle: A dynamic assembly of microtubules and motors. Nat Cell Biol 2001; 3: E28-34.
29. Gelfand VI, Bershadsky AD. Microtubule dynamics: Mechanism, regulation, and function. Annu Rev Cell Biol 1991; 7: 93-116.
30. McIntosh JR, Grishchuk EL, West RR. Chromosome-microtubule interactions during mitosis. Annu Rev Cell Dev Biol 2002; 18: 193-219.
31. Mitchison T, Kirschner M. Microtubule assembly nucleated by isolated centrosomes. Nature 1984; 312: 232-237.
32. Mitchison T, Kirschner M. Dynamic instability of microtubule growth. Nature 1984; 312: 237-242.
33. Margolis RL, Wilson L. Microtubule treadmilling: What goes around comes around. Bioessays 1998; 20: 830-836.
34. Wilson L, Jordan MA. Microtubule dynamics: Taking aim at a moving target. Chem Biol 1995; 2: 569-673.
35. Farrell KW, Jordan MA, Miller HP, et al. Phase dynamics at microtubule ends: The coexistence of microtubule length changes and treadmilling. J Cell Biol 1987; 104: 1035-1046.
36. Margolis RL, Wilson L. Microtubule treadmills - possible molecular machinery. Nature 1981; 293: 705-711.
37. Schulze E, Kirschner M. New features of microtubule behaviour observed in vivo. Nature 1988; 334: 356-359.
38. Mitchison T, Kirschner M. Cytoskeletal dynamics and nerve growth. Neuron 1988; 1: 761-72.
39. Koshland DE, Mitchison TJ, Kirschner MW. Polewards chromosome movement driven by microtubule depolymerization in vitro. Nature 1988; 331: 499-504.
40. Kirschner MW, Mitchison T. Microtubule dynamics. Nature 1986; 324: 621.
41. Mitchison T, Evans L, Schulze E, et al. Sites of microtubule assembly and disassembly in the mitotic spindle. Cell 1986; 45: 515-527.
42. Nogales E, Wolf SG, Downing KH. Structure of the α β tubulin dimer by electron crystallography. Nature 1998; 391: 199-203.
43. Williams RF, Mumford CL, Williams GA, et al. A photoaffinity derivative of colchicine: 6′-(4′-Azido-2′-nitrophenylamino) hexanoyldeacetylcolchicine. Photolabeling and location of the colchicine-binding site on the alpha-subunit of tubulin. J Biol Chem 1985; 260: 13794-131802.
44. Safa AR, Hamel E, Felsted RL. Photoaffinity labeling of tubulin subunits with a photoactive analogue of vinblastine. Biochem 1987; 26: 97-102.
45. Horwitz SB. Taxol (paclitaxel): Mechanisms of action. Ann Oncol 1994; 5: S3-S6.
46. Rai SS, Wolff J. Localization of the vinblastine-binding site on beta-tubulin. J Biol Chem 1996; 271: 14707-4711.
47. Jordan A, Hadfield JA, Lawrence NJ, et al. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Med Res Rev 1998; 18: 259-296.
48. Correia JJ, Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr Pharm Des 2001; 7: 1213-1228.
49. Ngan VK, Bellman K, Panda D, et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 2000; 60: 5045-5051.
50. Shih C, Teicher BA. Cryptophycins: A novel class of potent antimitotic antitumor depsipeptides. Curr Pharm Des 2001; 7: 1259-1276.
51. Leoni LM, Hamel E, Genini D, et al. Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J Natl Cancer Inst 2000; 92: 217-224.
52. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 2001; 127: 405-410.
53. Tahir SK, Han EK, Credo B, et al. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res 2001; 61: 5480-5485.
54. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665-667.
55. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochem 1981; 20: 3247-3252.
56. Nogales E. A structural view of microtubule dynamics. Cell Mol Life Sci 1999; 56: 133-142.
57. Snyder JP, Nettles JH, Cornett B, et al. The binding conformation of Taxol in β-tubulin: A model based on electron crystallographic density. Proc Natl Acad Sci USA 2001; 98: 5312-5316.
58. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007; 6: 609-621.
59. Parness J, Kingston DG, Powell RG, et al. Structure-activity study of cytotoxicity and microtubule assembly in vitro by taxol and related taxanes. Biochem Biophys Res Commun 1982; 105: 1082-1089.
60. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353-374.
61. Cassidy PB, Moos PJ, Kelly RC, et al. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: Structure-activity relationships and their implications. Clin Cancer Res 2002; 8: 846-855.
62. Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 1992; 52: 119-121.
63. Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: Induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 1998; 95: 3896-3901.
64. White CM, Martin BK, Lee LF, et al. Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother. 1998; 46: 104-112.
65. Napoleone E, Zurlo F, Latella MC, et al. Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells. Eur J Cancer 2009; 45: 470-477.
66. Altaha R, Fojo T, Reed E, et al. Epothilones: A novel class of non-taxane microtubule-stabilizing agents. Curr Pharm Des 2002; 8: 1707-1712.
67. Kowalski RJ, Giannakakou P, Gunasekera SP, et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997; 52: 613-622.
68. Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006; 5: 270-278.
69. Larkin JM, Kaye SB. Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 2007; 18 (Suppl 5): v28-34.
70. Altmann KH. Microtubule-stabilizing agents: A growing class of important anticancer drugs. Curr Opin Chem Biol 2001; 5: 424-431.
71. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov Today 2001; 6: 1153-1164.
72. Madari H, Panda D, Wilson L, et al. Dicoumarol: A unique microtubule stabilizing natural product that is synergistic with Taxol. Cancer Res 2003; 63: 1214-1220.
73. Pryor DE, O'Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochem 2002; 41: 9109-9115.
74. Hood KA, West LM, Rouwé B, et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res 2002; 62: 3356-3360.
75. Panda D, Miller HP, Banerjee A, et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 1994; 91: 11358-11362.
76. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20: 1-15.
77. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-1268.
78. DeMario MD, Ratain MJ. Oral chemotherapy: Rationale and future directions. J Clin Oncol 1998; 16: 2557-2567.
79. Bardelmeijer HA, Ouwehand M, Beijnen JH, et al. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 2004; 22: 219-229.
80. Huizing MT, Giaccone G, van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 1997; 15: 317-329.
81. Schellens JH, Malingré MM, Kruijtzer CM, et al. Modulation of oral bioavailability of anticancer drugs: From mouse to man. Eur J Pharm Sci 2000; 12: 103-110.
82. Gerrits CJ, Schellens JH, Creemers GJ, et al. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. Br J Cancer 1997; 76: 946-951.
83. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-2035.
84. Checchi PM, Nettles JH, Zhou J, et al. Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci 2003; 24: 361-365.
85. Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-9556.
86. Wang Y, O'Brate A, Zhou W, et al. Resistance to microtubule-stabilizing drugs involves two events: β-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 2005; 4: 1847-1853.
87. Drukman S, Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents (review). Int J Oncol 2002; 21: 621-628.
88. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-283.
89. Yamada T, Mori Y, Hayashi R, et al. Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res 2003; 63: 895-901.
90. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003; 63: 1515-1519.
91. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000; 97: 2904-2409.
92. Cowan NJ, Dudley L. Tubulin isotypes and the multigene tubulin families. Int Rev Cytol 1983; 85: 147-173.
93. Joshi HC, Cleveland DW. Diversity among tubulin subunits: Toward what functional end? Cell Motil Cytoskeleton 1990; 16: 159-163.
94. Roach MC, Boucher VL, Walss C, et al. Preparation of a monoclonal antibody specific for the class I isotype of beta-tubulin: The beta isotypes of tubulin differ in their cellular distributions within human tissues. Cell Motil Cytoskeleton 1998; 39: 273-285.
95. Burkhart CA, Kavallaris M, Band Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001; 1471: 1-9.
96. Kavallaris M, Tait AS, Walsh BJ, et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61: 5803-5809.
97. Graf WD, Chance PF, Lensch MW, et al. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996; 77: 1356-1362.
98. Khan, S.R., Hallur, G., Hidalgo, M., Jimeno, A.: US20090099218A1 (2009).
99. Balcer-Kubiczek EK, Attarpour M, Edelman MJ. The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines. Cancer Chemother Pharmacol 2007; 59: 781-787.
100. Hallur G, Jimeno A, Dalrymple S, et al. Benzoylphenylurea sulfur analogues with potent antitumor activity. J Med Chem 2006; 49: 2357-2360.
101. Jimeno A, Hallur G, Chan A, et al. Efficacy of novel BPU analogs in in vitro and in novel in vivo pancreas cancer models, and its relationship with microtubule associated protein tau (MAPT). AACR-NCI-EORTC International Conference. Philadelphia, USA, November 2005.
102. Desai, N.P., Soon-Shiong, P.: WO2008150532A1 (2008).
103. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008; 60: 876-885.
104. Desai, N.P., Tao, C., Yang, A., Louie, L., Zheng, T., Yao, Z., Soon-Shiong, P., Magdassi, S.: US5916596 (1999).
105. Desai, N.P., Soon-Shiong, P.: US20006096331 (2000).
106. Desai, N.P., Tao, C., Yang, A., Louie, L., Zheng, T., Yao, Z., Soon-Shiong, P., Magdassi, S.: US20006749868 (2000).
107. Desai, N.P., Soon-Shiong, P.: US20030199425 (2003).
108. Desai, N.P., Tao, C., Yang, A., Louie, L., Zheng, T., Yao, Z., Soon-Shiong, P., Magdassi, S.: WO98014174A1 (1998).
109. Desai, N.P., Soon-Shiong, P., Magdassi, S., Sahadevan, D.C.: WO99000113A1 (1999).
110. De, T., DesaiI, N.P., Yang, A., Yim, Z., Soon-Shiong, P.: WO2007027941A2 (2007).
111. DesaiI, N.P., Selvraj, R., Yang, A., Soon-Shiong, P.: WO2007027819A2 (2007).
112. Micha JP, Goldstein BH, Birk CL, et al. Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions. Gynecol Oncol 2006; 100: 437-438.
113. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nano-particle formulation of paclitaxel. Clin Cancer Res 2002; 8: 1038-1044.
114. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005; 23: 6019-26.
115. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-7803.
116. Ishiguro, K., Gotoh, H., Andoh, T.: WO2008139952A1 (2008).
117. Ishiguro K, Ando T, Watanabe O, et al. Specific reaction of alpha, beta-unsaturated carbonyl compounds such as 6-shogaol with sulfhydryl groups in tubulin leading to microtubule damage. FEBS Lett 2008; 582: 3531-3536.
118. Ishiguro K, Ando T, Maeda O, et al. Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms. Biochem Biophys Res Commun 2007; 362: 218-23.
119. Brown, M. L., Laurel. M.D.: US20070244098A1 (2007).
120. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002; 2: 1-17.
121. Tinley TL, Leal RM, Randall-Hlubek DA, et al. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res 2003; 63: 1538-1549.
122. Pruitt III FL, Evans A, Lynch JE, et al. The effect of a novel thalidomide analog, SC-2-71, on caspase activity in human bone endothelial cells. Proc Am Assoc Cancer Res 2006; 47: abstract 1349.
123. Martin, S., Whipple, R.: WO2007104011A2 (2007).
124. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-626.
125. Nikiforov MA, Hagen K, Ossovskaya VS, et al. Modulation of anchorage independent growth and experimental metastasis. Oncogene 1996; 13: 1709-1719.
126. Nikiforov MA, Kwek SS, Mehta R, et al. Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence. Oncogene 1997; 15: 3007-3012.
127. Korb T, Schlüter K, Enns A, et al. Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion. Exp Cell Res 2004; 299: 236-247.
128. Davis, A. S., Middleton, K.M., Jiang, J.D., Bekesi, J.G.: US20077259278 (2007).
129. Davis A, Jiang JD, Middleton KM, et al. Novel suicide ligands of tubulin arrest cancer cells in S-phase. Neoplasia 1999; 1: 498-507.
130. Shan B, Medina JC, Santha E, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci USA 1999; 96: 5686-5691.
131. Jiang JD, Denner L, Ling YH, et al. Double blockade of cell cycle at G(1)-S transition and M phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand. Cancer Res 2002; 62: 6080-6088.
132. Dey S, Ramachandra M, Pastan I, et al. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 1997; 94: 10594-10599.
133. Parker C, Lakshmi MS, Piura B, et al. Metastasis-associated mts1 gene expression correlates with increased p53 detection in the B16 murine melanoma. DNA Cell Biol 1994; 13: 343-351.
134. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99: 2060-2069.
135. Giavazzi R, Bonezzi K, Taraboletti G. The role of microtubules in cell biology, neurobiology, and oncology. Microtubule targeting agents and the tumor vasculature. Springer: USA 2008; 519-530.
136. Vitale I, Antoccia A, Cenciarelli C, et al. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis 2007; 12: 155-166.
137. Pinney, K.G., Sriram, M.: US20060293394A1 (2006).
138. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19: 189-195.
139. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 1999; 59: 1626-1634.
140. Pettit GR, Rhodes MR. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des 1998; 13: 183-191.
141. Iyer S, Chaplin DJ, Rosenthal DS, et al. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998; 58: 4510-4514.
142. Dark GG, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829-1834.
143. George, R.P.: US5561122 (1996).
144. West CM, Price P. Combretastatin A4 phosphate. Anticancer Drugs 2004; 15: 179-187.
145. Petit I, Karajannis MA, Vincent L, et al. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 2008; 111: 1951-1961.
146. Hadimani MB, Hua J, Jonklaas MD, et al. Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. Bioorg Med Chem Lett 2003; 13: 1505-1508.
147. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62: 7247-7253.
148. Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008; 43: 100-111.
149. Agoulnik, S., Kuznetsov, G., Littlefield, B.A.: US20060154312A1 (2006).
150. Agoulnik, S., Kuznetsov, G., Littlefield, B.A.: US20060148014A1 (2006).
151. Gaudreault, R.C., Legault, J.: US20050250853A1 (2005).
152. Gaudreault, R.C., Patrick P.: US5530026 (1996).
153. Gaudreault, R.C., Patrick P.: US5750547 (1998).
154. Sanderson BJ, Shield AJ. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res 1996; 355: 41-57.
155. Papadopoulos, P., Doty, M., Kipp, J.E., Roessler, B.: WO2006052712A1 (2006).
156. Wienecke A, Bacher G. Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin. Cancer Res 2009; 69: 171-177.
157. Guillaume, L., Cecilia, M., Bernhard, K., Peter, E., Stefan, S., Kay, B.: US6008231 (1999).
158. Bernd N., Istvan, S., Jürgen S., Peter, E., Dietmar, R., Eckhard, G., Kay, B.: US20016232327 (2001).
159. Bernd, N., Gerald, B., Thomas, K., Thomas, B., Peter, E., Jürgen, E., Erik, B., Günter, K., Kirsten, P.: US20046693119 (2004).
160. Bacher G, Nickel B, Emig P, et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 2001; 61: 392-399.
161. Oostendorp RL, Witteveen PO, Schwartz B, et al. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Invest New Drugs 2009.
162. Owa, T., Ozawa, Y., Semba, T., Hata, N.: US20090047365A1 (2009).
163. Haneda, T., Tsurukova, A., Kamata, J., Okabe, T., Takahashi, K., Nara, K., Hamoka, S., Ueda, N., Ohwa, T., Wakabayashi, T., Funahashi, Y., Semba, T., Hata, N., Yamamoto, Y., Ozawa, Y., Tsukahara, N.: WO0050395A1 (2000).
164. Rose WC, Wild R. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts. Clin Cancer Res 2004; 10: 7413-7417.
165. Levy C, Fumoleau P. Gemcitabine plus docetaxel: A new treatment option for anthracycline pretreated metastatic breast cancer patients? Cancer Treat Rev 2005; 31: S17-22.
166. Markland, F.S., Swenson, S., Pinski, J.L.: US20080064634A1 (2008).
167. Trikha M, Rote WE, Manley PJ, et al. Purification and characterization of platelet aggregation inhibitors from snake venoms. Thromb Res 1994; 73: 39-52.
168. Swenson S, Ramu S, Markland FS. Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des 2007; 13: 2860-2871.
169. Ye K, Ke Y, Keshava N, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA. 1998; 95: 1601-1616.
170. 2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 2002; 277: 39777-39785.
171. Mahmoudian M, Rahimi-Moghaddam P. The anti-cancer activity of noscapine: A review. Recent Pat Anticancer Drug Discov 2009; 4: 92-97.
172. Landen JW, Lang R, McMahon SJ, et al. Noscapine alters microtubule dynamics in living cells and inhibits theprogression of melanoma. Cancer Res 2002; 62: 4109-4114.
173. Ke Y, Ye K, Grossniklaus HE, et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000; 49: 217-225.
174. Aneja R, Zhou J, Vangapandu SN, et al. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 2006; 107: 2486-2492.
175. Landen JW, Hau V, Wang M, et al. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004; 10: 5187-5201.
176. Aneja R, Dhiman N, Idnani J, et al. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 2007; 60: 831-839.
177. Zhou J, Gupta K, Aggarwal S, et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 2003; 63: 799-807.
178. Aneja R, Vangapandu SN, Lopus M, et al. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol 2006; 72: 415-426.
179. Aneja R, Liu M, Yates C, et al. Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent. Cancer Res 2008; 68: 1495-1503.
180. Aneja R, Kalia V, Ahmed R, et al. Nonimmunosuppressive chemotherapy: EM011-treated mice mount normal T-cell responses to an acute lymphocytic choriomeningitis virus infection. Mol Cancer Ther 2007; 6: 2891-2899.
181. Aneja R, Lopus M, Zhou J, et al. Rational design of the microtubule-targeting anti-breast cancer drug EM015. Cancer Res 2006; 66: 3782-3791.
182. Joshi, H.C., Keqiang, Y., Kapp, J., Liu, F.: US20026376516 (2002).
183. Joshi, H.C., Keqiang, Y., Kapp, J., Landen, J., Archer, D., Armstrong, C., Liu, F.: US20046673814 (2004).
184. Kapp, J., Ke, Y.: US20067090853 (2006).
185. Ivashchenko, A.V., Kysil, V.M., Khvat, A.V., Malyarchuk, S.V., Okun, I.M., Tkachenko, S. Y., Kyselev, A.S.: WO2007133112A1 (2007).
186. Aneja, R., Joshi, H.C., Vandapandu, S.N.: WO2008109609A1 (2008).
187. Chandra, R.: WO2008109614A1 (2008).